CaPre
Acasti’s shares plunge as new drug does not meet primary endpoint
January 14, 2020Manufacturing and Production Acasti, Acasti Pharma, CaPre, Primary Endpoint, Shares
Acasti Pharma’s shares plunged by as much as 67% this week as its drug CaPre failed to meet its primary …
Latest content
Acumentis CEO Herspiegel steps down as Burden assumes role
October 27, 2026
October 26, 2026
